Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | NAMPT | P43490 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811181 | 0.84 | PARP1 (0.53) | PARP1ROCK2NAMPTROCK1 | |
| SCHEMBL4810830 | 0.82 | PARP1 (0.53) | PARP1NAMPT | |
| SCHEMBL4812985 | 0.81 | PARP1 (0.52) | PARP1ROCK2NAMPTROCK1HRH3 | |
| SCHEMBL4812987 | 0.81 | PARP1 (0.52) | PARP1ROCK2NAMPTROCK1HRH3 | |
| SCHEMBL4813426 | 0.80 | PARP1 (0.51) | PARP1ROCK2NAMPTROCK1ACHE | |
| SCHEMBL4154686 | 0.77 | PARP1 (1.00) | PARP1ROCK2NAMPTROCK1HRH3 | |
| SCHEMBL30859698 | 0.77 | PARP1 (1.00) | PARP1ROCK2NAMPTROCK1HRH3 | |
| SCHEMBL14064676 | 0.77 | PARP1 (0.65) | PARP1CDK4CCND1 | |
| SCHEMBL14064732 | 0.76 | PARP1 (0.65) | PARP1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL4816152 | 0.76 | PARP1 (0.98) | PARP1ROCK2NAMPTROCK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425563-B2 | Excellent poly (ADP-ribose) synthetase inhibitors; various ischemic diseases, inflammatory diseases, neurodegenerative diseases, diabetes, septic shock, cephalic injury; 1,2-Dihydro-4-[4-(dimethylaminomethyl)phenyl]-5-hydroxy-1-oxoisoquinoline | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | claimed |
| US-20060173039-A1 | 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-03 | — | — | US | claimed |
| EP-1544194-A1 | 4-(SUBSTITUTED ARYL)-5-HYDROXYISOQUINOLINONE DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173039-A1 | 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative | PARP1, PARP11, PARP4 | PARP1 1/4885ROCK2 3947/4885NAMPT 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.